Molecular subtyping of breast cancer patients with long time follow up and its prognostic value on survival: a single center analysis


ELİYATKIN N. Ö., AKTAŞ S., Zengel B., Postaci H., Uslu A., Yagci A.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.9, no.6, pp.11526-11533, 2016 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 6
  • Publication Date: 2016
  • Journal Name: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.11526-11533
  • Keywords: Breast cancer, molecular subtype, prognosis, survival, EGYPTIAN WOMEN, CLASSIFICATION, CARCINOMA, REGISTRY, COHORT, PREDICTION, GUIDELINES, FEATURES, CHINA
  • Dokuz Eylül University Affiliated: Yes

Abstract

The importance of molecular subtyping in breast cancer is an unresolved issue. In this study we aimed to evaluate the significance of molecular subtyping, and the correlation between the disease-free, and overall survival in breast cancer based on molecular subtypes. A total of 536 patients with the diagnosis of breast cancer between the years 1980 and 2014 were included in the study. Tumors were divided into five molecular subtypes according to their expression profiles as follows: Luminal A: (n=220; 41%); Luminal B: (n=72; 13.4%); Luminal B-like: (n=97, 18.1%); HER2: (n=44; 8.2%); and Triple-negative (n=103; 19.2%). We found significant differences between molecular subtypes, and histological subtype of the tumor (P=0.004) in terms of local recurrence (P=0.043), and metastasis (P=0.006). A statistically significant difference was found between the number of metastases, and molecular subgroups. (P=0.037). Among all molecular subtypes, local recurrences (11.4%), and metastasis (38.6%) were most frequently seen in the HER2 subtype, while the least number of metastases (15.3%) were detected in the Luminal A subtype. A statistically significant difference was found between Luminal A, and HER2 subgroups as for incidence of metastatic lesions (P=0.007). However in the Luminal A subgroup metastases developed in the long term (at the end of 50 months after onset of the disease). Overall, and disease-free survival curves in the Luminal A subgroup indicated risk of mortality in the long run. Based on molecular subtyping the worst, and the most favourable survival rates were observed in the HER2, and Luminal A subgroups, respectively. Impact: In this study which encompassed multiple number of breast cancer patients encountered within 30 years, HER2 tumors had the worst survival rates Interestingly, Luminal A subgroup which displayed a very favourable prognosis during the early stage of the follow-up period, demonstrated a bad prognosis in the long term.